Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine

[1]  M. Weller,et al.  O6‐methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells , 2006, Journal of neurochemistry.

[2]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[3]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[4]  M. O'Connell,et al.  G2 damage checkpoints: what is the turn-on? , 2005, Journal of Cell Science.

[5]  M. J. Hickman,et al.  Apoptotic signaling in response to a single type of DNA lesion, O(6)-methylguanine. , 2004, Molecular cell.

[6]  B. Kaina,et al.  Loss of ATM sensitizes against O6-methylguanine triggered apoptosis, SCEs and chromosomal aberrations. , 2004, DNA repair.

[7]  S. Gerson.  MGMT: its role in cancer aetiology and cancer therapeutics , 2004, Nature Reviews Cancer.

[8]  I. Germano,et al.  Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells , 2004, Cell Death and Differentiation.

[9]  Luca Regli,et al.  Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide , 2004, Clinical Cancer Research.

[10]  B. Kaina,et al.  Apoptosis triggered by DNA damage O6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas/CD95/Apo-1 , 2004, Oncogene.

[11]  M. Weller,et al.  CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death , 2003, Oncogene.

[12]  B. Kaina,et al.  Apoptosis induced by MNNG in human TK6 lymphoblastoid cells is p53 and Fas/CD95/Apo-1 related. , 2003, Mutation research.

[13]  K. Aktories,et al.  His1205 and His1223 are essential for the activity of the mitogenic Pasteurella multocida toxin. , 2003, Biochemistry.

[14]  S. Shibata,et al.  Relationship between expression of O6-methylguanine-DNA methyltransferase, glutathione-S-transferase π in glioblastoma and the survival of the patients treated with nimustine hydrochloride: An immunohistochemical analysis , 2003, Neurological research.

[15]  B. Kaina,et al.  DNA repair protein MGMT protects against N-methyl-N-nitrosourea-induced conversion of benign into malignant tumors. , 2003, Carcinogenesis.

[16]  E Pawlak,et al.  Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids , 2003, British Journal of Cancer.

[17]  J. Jiricny,et al.  The Effect of O 6-Alkylguanine-DNA Alkyltransferase and Mismatch Repair Activities on the Sensitivity of Human Melanoma Cells to Temozolomide, 1,3-bis(2-Chloroethyl)1-nitrosourea, and Cisplatin , 2003, Journal of Pharmacology and Experimental Therapeutics.

[18]  M. Santibanez-Koref,et al.  O6-alkylguanine-DNA alkyltransferase: role in carcinogenesis and chemotherapy. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[19]  B. Kaina,et al.  DNA double-strand breaks trigger apoptosis in p53-deficient fibroblasts. , 2001, Carcinogenesis.

[20]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[21]  A. Pegg.  Repair of O6-alkylguanine by alkyltransferases , 2000 .

[22]  T. Lindahl,et al.  Suppression of spontaneous mutagenesis in human cells by DNA base excision-repair. , 2000, Mutation research.

[23]  M. J. Hickman,et al.  Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[24]  M. Weller,et al.  p53 Enhances BAK and CD95 Expression in Human Malignant Glioma Cells but Does Not Enhance CD95L-Induced Apoptosis , 1999, Cellular Physiology and Biochemistry.

[25]  D. Israeli,et al.  p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs , 1998, The Journal of experimental medicine.

[26]  L. Samson,et al.  O6-alkylguanine DNA lesions trigger apoptosis. , 1998, Carcinogenesis.

[27]  B. Kaina,et al.  Chromosomal instability, reproductive cell death and apoptosis induced by O6-methylguanine in Mex-, Mex+ and methylation-tolerant mismatch repair compromised cells: facts and models. , 1997, Mutation research.

[28]  G. Aquilina,et al.  Mismatch Repair Defects andO 6-Methylguanine-DNA Methyltransferase Expression in Acquired Resistance to Methylating Agents in Human Cells* , 1997, The Journal of Biological Chemistry.

[29]  Richard S Gates,et al.  Turing machine approach to solve psychrometric attributes , 1997 .

[30]  T. Tsuzuki,et al.  Alkylation-induced apoptosis of embryonic stem cells in which the gene for DNA-repair, methyltransferase, had been disrupted by gene targeting. , 1997, Carcinogenesis.

[31]  G. Dianov,et al.  Reduced RNA polymerase II transcription in intact and permeabilized Cockayne syndrome group B cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[32]  B. Kaina,et al.  Protective effect of O6‐methylguanine‐DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs , 1996, International journal of cancer.

[33]  R. Mirzayans,et al.  Radiation-induced DNA damage and repair in cells of a radiosensitive human malignant glioma cell line. , 1995, Radiation research.

[34]  S. Haas,et al.  O6‐methylguanine‐DNA methyltransferase activity in breast and brain tumors , 1995, International journal of cancer.

[35]  M. Tewari,et al.  Fas- and Tumor Necrosis Factor-induced Apoptosis Is Inhibited by the Poxvirus crmA Gene Product (*) , 1995, The Journal of Biological Chemistry.

[36]  P. Karran,et al.  DNA damage tolerance, mismatch repair and genome instability , 1994, BioEssays : news and reviews in molecular, cellular and developmental biology.

[37]  M. Dolan,et al.  Mechanism of inactivation of human O6-alkylguanine-DNA alkyltransferase by O6-benzylguanine. , 1993, Biochemistry.

[38]  W. Thilly,et al.  An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[39]  S. Gerson,et al.  The prevention of thymic lymphomas in transgenic mice by human O6-alkylguanine-DNA alkyltransferase. , 1993, Science.

[40]  B. Kaina,et al.  Transfection and expression of human O6-methylguanine-DNA methyltransferase (MGMT) cDNA in Chinese hamster cells: the role of MGMT in protection against the genotoxic effects of alkylating agents. , 1991, Carcinogenesis.

[41]  M. Dolan,et al.  Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[42]  D. Beranek.  Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents. , 1990, Mutation research.

[43]  R. Sklar,et al.  Removal of O6-methylguanine from DNA of normal and xeroderma pigmentosum-derived lymphoblastoid lines , 1981, Nature.

[44]  G. Stark,et al.  Transfer of proteins from gels to diazobenzyloxymethyl-paper and detection with antisera: a method for studying antibody specificity and antigen structure. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[45]  A. Binder,et al.  Determination of the initial DNA damage and residual DNA damage remaining after 12 hours of repair in eleven cell lines at low doses of irradiation. , 2000, International journal of radiation biology.